Avita Medical (RCEL)
(Real Time Quote from BATS)
$8.63 USD
+0.11 (1.29%)
Updated Apr 29, 2024 02:22 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCEL 8.63 +0.11(1.29%)
Will RCEL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RCEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCEL
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?
RCEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System
Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data
Other News for RCEL
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL) and CVRx (CVRX)
Wall Street Analysts Are Bullish on Top Healthcare Picks
AVITA Medical to Announce First Quarter 2024 Financial Results
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
NKTR, VERU and EGIO among mid-day movers